Published in Am J Gastroenterol on December 01, 2000
Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut (2004) 1.87
Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Gut (2007) 1.00
Treatment of complex perianal fistulas in Crohn disease: infliximab, surgery or combined approach. Can J Surg (2010) 0.99
Mannosylated bioreducible nanoparticle-mediated macrophage-specific TNF-α RNA interference for IBD therapy. Biomaterials (2013) 0.97
Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease. Genome Med (2013) 0.92
Infliximab for Crohn's disease: the first 500 patients followed up through 2009. Dig Dis Sci (2012) 0.92
Measurement of nutrition status in Crohn's disease patients receiving infliximab therapy. Nutr Clin Pract (2008) 0.90
Anti-Galectin-3 IgG autoantibodies in patients with Crohn's disease characterized by means of phage display peptide libraries. J Clin Immunol (2001) 0.89
Long-term durability of Crohn's disease treatment with infliximab. Dig Dis Sci (2007) 0.88
Dendritic cells a double-edge sword in autoimmune responses. Front Immunol (2012) 0.87
Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease. BMC Gastroenterol (2010) 0.86
Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort. Can J Gastroenterol (2009) 0.86
Risk of post-operative complications associated with anti-TNF therapy in inflammatory bowel disease. World J Gastroenterol (2012) 0.85
Pneumocystis pneumonia during combined therapy of infliximab, corticosteroid, and azathioprine in a patient with Crohn's disease. Dig Dis Sci (2007) 0.83
Laparoscopic treatment of Crohn's disease. World J Surg (2011) 0.83
Minimally invasive approaches for the treatment of inflammatory bowel disease. World J Gastroenterol (2012) 0.81
Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up. World J Gastroenterol (2007) 0.81
Interleukin 34: a new modulator of human and experimental inflammatory bowel disease. Clin Sci (Lond) (2015) 0.81
Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease. Expert Rev Clin Immunol (2010) 0.80
Infliximab to treat Crohn's disease: an update. Clin Exp Gastroenterol (2011) 0.78
Infliximab preferentially induces clinical remission and mucosal healing in short course Crohn's disease with luminal lesions through balancing abnormal immune response in gut mucosa. Mediators Inflamm (2015) 0.78
Effects of tripolyphosphate on cellular uptake and RNA interference efficiency of chitosan-based nanoparticles in Raw 264.7 macrophages. J Colloid Interface Sci (2016) 0.75
Ischaemic/reperfusion injury: Role of infliximab. World J Transplant (2012) 0.75
The critical role of macrophages in the pathogenesis of hidradenitis suppurativa. Inflamm Res (2017) 0.75
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature (2001) 28.24
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med (1997) 10.67
A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis (2000) 6.90
Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med (1999) 6.24
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut (2007) 4.21
Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2001) 3.85
Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1. Proc Natl Acad Sci U S A (1998) 2.88
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis (2001) 2.80
A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med (2000) 2.78
Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. A case-control study. Gastroenterology (1989) 2.66
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology (1999) 2.62
Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis (1999) 2.55
Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol (2001) 2.39
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology (2000) 2.23
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology (2000) 2.21
Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology (1999) 2.15
Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease. Aliment Pharmacol Ther (2013) 2.12
Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology (1993) 2.03
Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol (1999) 1.90
Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology (1999) 1.84
Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther (2005) 1.79
American families with Crohn's disease have strong evidence for linkage to chromosome 16 but not chromosome 12. Gastroenterology (1998) 1.71
Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis. Am J Gastroenterol (1993) 1.70
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology (2001) 1.57
Linkage heterogeneity for the IBD1 locus in Crohn's disease pedigrees by disease onset and severity. Gastroenterology (2000) 1.40
The menstrual cycle and its effect on inflammatory bowel disease and irritable bowel syndrome: a prevalence study. Am J Gastroenterol (1998) 1.35
Hazard rates for dysplasia and cancer in ulcerative colitis. Results from a surveillance program. Dig Dis Sci (1989) 1.34
Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial. Gut (1997) 1.32
A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol (2000) 1.31
Prevalence and incidence of inflammatory bowel disease in family members. Gastroenterology (1986) 1.26
Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther (2003) 1.20
Clostridium difficile culture-positive toxin-negative diarrhea. Am J Gastroenterol (1986) 1.20
Weight and body mass index predict bone mineral density and fractures in women aged 40 to 59 years. Osteoporos Int (2008) 1.15
Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf (2000) 1.15
Smoking and inflammatory bowel disease. Eur J Gastroenterol Hepatol (2000) 1.14
Colon cancer surveillance in chronic ulcerative colitis: historical cohort study. Am J Gastroenterol (1990) 1.11
Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study. Aliment Pharmacol Ther (2010) 1.07
Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology (1999) 1.05
Passive smoking is associated with an increased risk of developing inflammatory bowel disease in children. Am J Gastroenterol (1993) 1.04
Prediction of hip and other osteoporotic fractures from hip geometry in a large clinical cohort. Osteoporos Int (2009) 1.03
Disseminated Trichosporon beigelii (cutaneum). Cancer (1981) 1.02
Optimal timing of colonoscopy to screen for cancer in ulcerative colitis. Ann Intern Med (1988) 1.01
Cigarette smoking in Crohn's disease. Am J Gastroenterol (1989) 1.01
Dysplasia and cancer complicating strictures in ulcerative colitis. Dig Dis Sci (1990) 1.01
Testing nicotine gum for ulcerative colitis patients. Experience with single-patient trials. Dig Dis Sci (1990) 0.99
Infectious complications associated with hairy cell leukemia. J Infect Dis (1981) 0.98
Side-to-side isoperistaltic strictureplasty in extensive Crohn's disease: a prospective longitudinal study. Ann Surg (2000) 0.97
Linkage and linkage disequilibrium in chromosome band 1p36 in American Chaldeans with inflammatory bowel disease. Hum Mol Genet (2000) 0.97
Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol (2000) 0.97
A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin. Inflamm Bowel Dis (1999) 0.96
Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease. Aliment Pharmacol Ther (2013) 0.95
Circulating lymphocyte subpopulations in Crohn's disease. Gastroenterology (1983) 0.94
Confirmation of a susceptibility locus for Crohn's disease on chromosome 16. Inflamm Bowel Dis (1997) 0.92
Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591. Gastroenterology (1997) 0.88
Lack of association between oral contraceptive use and Crohn's disease: a community-based matched case-control study. Gastroenterology (1989) 0.88
Medical therapy for inflammatory bowel disease. Gastroenterol Clin North Am (1999) 0.88
Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment Pharmacol Ther (2003) 0.87
Cigarette smoking and ulcerative colitis: a case-control study. Mayo Clin Proc (1994) 0.87
Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease. Aliment Pharmacol Ther (2011) 0.86
Pattern and prognosis of liver function test abnormalities during parenteral nutrition in inflammatory bowel disease. Hepatology (1985) 0.86
Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro. Comparison with sulfasalazine and 5-aminosalicylic acid. Gastroenterology (1988) 0.86
Factors predicting osteoporosis treatment initiation in a regionally based cohort. Osteoporos Int (2008) 0.85
Preoperative total parenteral nutrition for bowel resection in Crohn's disease. Dig Dis Sci (1989) 0.85
Acute leukemia following inflammatory bowel disease. Dig Dis Sci (1982) 0.84
Lack of association between oral contraceptive use and ulcerative colitis. Gastroenterology (1990) 0.84
Morbidity of subtotal colectomy in patients with severe ulcerative colitis unresponsive to cyclosporin. Dis Colon Rectum (1995) 0.81
Crohn's disease. Curr Probl Surg (1993) 0.81
Efficacy of parenteral methotrexate in refractory Crohn's disease. Aliment Pharmacol Ther (2001) 0.81
Protein-losing enteropathy and massive pulmonary embolism in a patient with giant inflammatory polyposis and quiescent ulcerative colitis. Am J Med (1996) 0.81
Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies. Aliment Pharmacol Ther (2002) 0.80
A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. Aliment Pharmacol Ther (2005) 0.78
Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. Aliment Pharmacol Ther (2004) 0.78
Smoking and inflammatory bowel disease in families. Am J Gastroenterol (1988) 0.78
Duration of recurrent ileitis after ileocolonic resection correlates with presurgical extent of Crohn's disease. Gut (1995) 0.78
Pneumocystis carinii pneumonia during cyclosporine therapy for ulcerative colitis. N Engl J Med (1992) 0.78
Medical therapy to reduce postoperative Crohn's disease recurrence. Am J Gastroenterol (2000) 0.77
Nicotine for colitis--the smoke has not yet cleared. N Engl J Med (1994) 0.76
Medical management of Crohn's disease. Drugs Today (Barc) (1998) 0.76
European evidence-based consensus on the diagnosis and management of Crohn's disease. Gut (2007) 0.76
Acute pancreatitis associated with high-concentration lipid emulsion during total parenteral nutrition therapy for Crohn's disease. Gastroenterology (1986) 0.76
Protection from primary sclerosing cholangitis: smoke trails of just coattails? Gastroenterology (1996) 0.75
Commentary: pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with ulcerative colitis. Aliment Pharmacol Ther (2012) 0.75
pANCA and classification resistance in ulcerative colitis. Mayo Clin Proc (1996) 0.75
Surveillance colonoscopy in ulcerative colitis: is the message loud and clear? Am J Gastroenterol (1995) 0.75
Surveying surveillance: are gastroenterologists consistently inconsistent, inconsistently consistent, or poorly educated? Gastrointest Endosc (2000) 0.75
Selected individual therapeutic problems in inflammatory bowel disease. Am J Gastroenterol (1984) 0.75
A registry of clinical trials. Inflamm Bowel Dis (1996) 0.75
Medical management of perianal Crohn's disease. Semin Gastrointest Dis (1998) 0.75
Sulfasalazine vs. steroids in Crohn's disease: David vs. Goliath? Gastroenterology (1991) 0.75
The absence of an association between oral contraceptive use and ulcerative colitis in patients. Gastroenterology (1991) 0.75
Review article: the medical management of Crohn's disease. Aliment Pharmacol Ther (1996) 0.75
Best of DDW 2001. Highlights from the 2001 Digestive Disease Week. May 20-23, 2001, Atlanta, GA. Rev Gastroenterol Disord (2001) 0.75
Crohn's disease. The problem and its management. Hosp Pract (Off Ed) (1984) 0.75
Non-Hodgkin's lymphoma presenting nine years after ileal-pouch ileoanal anastomosis for ulcerative colitis. Am J Gastroenterol (1998) 0.75
Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow? Gastroenterol Clin Biol (2009) 0.75
Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol. Aliment Pharmacol Ther (2011) 0.75